Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 1.00 |
| ▸ | NPY5R | Q15761 | 11/20 | 0.57 |
| ▸ | HPGDS | O60760 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5292919 | 0.80 | CYP2A6 (0.67) | CYP2A6NPY5RHPGDS | |
| SCHEMBL24427670 | 0.79 | CYP2A6 (0.65) | CYP2A6NPY5RHPGDS | |
| SCHEMBL19390541 | 0.78 | CYP2A6 (0.64) | CYP2A6NPY5RHPGDSCYP3A4CYP2E1 | |
| SCHEMBL13663126 | 0.78 | MASP2 (0.67) | CYP2A6NPY5RHPGDSCYP3A4CYP2E1 | |
| SCHEMBL3993735 | 0.78 | CYP2A6 (0.64) | CYP2A6NPY5RHPGDSCYP3A4CYP2E1 | |
| SCHEMBL13115273 | 0.77 | NPY5R (0.69) | CYP2A6NPY5RHPGDS | |
| SCHEMBL2319578 | 0.77 | NPY5R (0.69) | CYP2A6NPY5RHPGDS | |
| SCHEMBL15747127 | 0.77 | CYP2A6 (0.62) | CYP2A6NPY5RHPGDS | |
| SCHEMBL27815625 | 0.76 | NPY5R (0.87) | CYP2A6NPY5RHPGDS | |
| SCHEMBL18122017 | 0.76 | NPY5R (0.89) | CYP2A6NPY5RHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-3998263-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| US-9809545-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2978425-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160046581-A1 | Factor XIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046581-A1 | Factor XIa Inhibitors | F11, F12, TFPI | CYP2A6 2396/4885NPY5R 1124/4885HPGDS 1310/4885 |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | CYP2A6 930/4885NPY5R 873/4885HPGDS 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.